
Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
Panelists discuss how effective communication about amyloid-targeting therapies requires transparent discussions of modest cognitive benefits alongside potential risks, particularly events related to amyloid-related imaging abnormalities (ARIA), while addressing practical considerations including treatment burden, infusion center logistics, monitoring requirements, costs, insurance coverage, and caregiver involvement to help patients and families make fully informed decisions aligned with their values and circumstances.
Video content above is prompted by the following:
- How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the infusion center, etc?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.